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Background: The recently published GOLD guidelines provide a new system for staging chronic
obstructive pulmonary disease (COPD) from mild (stage I) to very severe (stage IV) and introduce a stage 0
(chronic cough and phlegm without airflow obstruction) that includes subjects ‘‘at risk’’ of developing the
disease.
Methods: In order to assess the prevalence of GOLD stages of COPD in high income countries and to
evaluate their association with the known risk factors for airflow obstruction, data from the European
Community Respiratory Health Survey on more than 18 000 young adults (20–44 years) were analysed.
Results: The overall prevalence was 11.8% (95% CI 11.3 to 12.3) for stage 0, 2.5% (95% CI 2.2 to 2.7) for
stage I, and 1.1% (95% CI 1.0 to 1.3) for stages II–III. Moderate to heavy smoking (>15 pack years) was
significantly associated with both stage 0 (relative risk ratio (RRR) = 4.15; 95% CI 3.55 to 4.84) and stages
I+ (RRR = 4.09; 95% CI 3.17 to 5.26), while subjects with stages I+ COPD had a higher likelihood of giving
up smoking (RRR = 1.39; 95% CI 1.04 to 1.86) than those with GOLD stage 0 (RRR = 1.05; 95% CI 0.86 to
1.27). Environmental tobacco smoke had the same degree of positive association in both groups.
Respiratory infections in childhood and low socioeconomic class were significantly and homogeneously
associated with both groups, whereas occupational exposure was significantly associated only with stage
0. All the GOLD stages showed a significantly higher percentage of healthcare resource users than healthy
subjects (p,0.001), with no difference between stage 0 and COPD.
Conclusions: A considerable percentage of young adults already suffered from COPD. GOLD stage 0 was
characterised by the presence of the same risk factors as COPD and by the same high demand for medical
assistance.
T
he recently published Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines provide a
new system for staging chronic obstructive pulmonary
disease (COPD) from mild (stage I) to very severe (stage IV).1
As a new approach, the GOLD guidelines have introduced a
stage 0 which represents absence of airflow obstruction but
presence of chronic symptoms such as cough and phlegm.
This stage is meant to include subjects ‘‘at risk’’ of developing
COPD later in life and to allow intervention while the disease
is not yet a health problem. The simple classification of the
disease severity into five stages is based on airflow obstruc-
tion as measured by spirometry, which is essential for
diagnosis and provides a useful description of the severity
of COPD.
The GOLD pragmatic approach, which aims at practical
implementation of management, can also be useful for case
identification and assessment of disease severity in epide-
miological studies. In fact, the imprecise and variable
definitions of COPD have so far made it hard to quantify
the morbidity of this disease and to compare its variation
between countries.2 The specific forced expiratory volume in
1 second (FEV1) cut off points of the GOLD staging, although
not yet clinically validated, could allow an estimation of
COPD severity in the general population which might help to
optimise the allocation of healthcare resources.
COPD is most often diagnosed in the fifth or sixth decades,
but there is already some evidence that it starts much earlier
in life.3–6 Only longitudinal studies of the younger population
could allow early detection of the disease; they might
highlight the natural history of those in the different GOLD
stages and offer assessment of the likelihood of the disease
progressing towards more severe stages.
The aim of the present study was to assess the prevalence
of COPD severity stages, as defined in the GOLD guidelines,
in high income countries and to evaluate whether subjects
with stage 0 disease and those with more severe stages share
a common pattern of risk factors and use of healthcare
resources. Data from the European Community Respiratory
Health Survey (ECRHS)7 were used. This study collected
information about health status, lung function, and other
factors known or hypothesised to be associated with COPD3
in more than 18 000 young adults (20–44 years) enrolled
between 1991 and 1993 throughout the European Union and
elsewhere. The results reported here are from 35 centres in 16
countries. The ongoing ECRHS II study8 will allow the follow
up of these subjects over time and their transition through
the GOLD stages.
METHODS
Study design and subjects
The full protocol of the ECRHS has been described else-
where.7 9 Briefly, each participating centre selected an area of
at least 150 000 inhabitants, defined by pre-existing admin-
istrative boundaries, and with an up to date sampling frame.
In the first stage of the study, randomly selected samples of
at least 1500 people of each sex, aged 20–44 years, were sent a
screening questionnaire enquiring about respiratory symp-
toms, attacks of asthma, use of asthma medications, and hay
fever or nasal allergies. In the second stage of the study a
random sample of subjects who had completed the screening
questionnaire was invited to come for a set of clinical and
functional tests, including a standardised clinical interview
and an assessment of lung function by spirometry.
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For the purpose of the present analysis we considered all
the subjects who participated in the second stage of the
ECRHS (table 1).
Methods
According to the ECRHS protocol, baseline FEV1 and forced
vital capacity (FVC) were measured in all the subjects who
consented. Up to five forced expiratory manoeuvres were
performed and the highest FEV1 and FVC that did not exceed
the next highest one by more than 5% were considered
for the present analysis. The questions on chronic symp-
toms and asthma used in the ECRHS were those of the
1976 version of the British Medical Research Council
Questionnaire.10
Staging was defined according to the GOLD guidelines1 as
follows:
N stage 0 (at risk): presence of chronic symptoms (cough
and/or phlegm from the chest, usually in winter and on
most days for as long as 3 months each year) at the
clinical interview and FEV1/FVC >70%;
N stage I (mild COPD): FEV1/FVC ,70% and FEV1 >80%
predicted;11
N stage II (moderate COPD): FEV1/FVC ,70% and FEV1 50–
80% predicted;
N stage III (severe COPD): FEV1/FVC ,70% and FEV1 30–
50% predicted;
N stage IV (very severe COPD): FEV1/FVC ,70% and FEV1
,30% predicted.
Subjects in stages I–IV could have or not have chronic
symptoms.
Asthma was considered present if a subject replied
affirmatively to the question ‘‘Have you ever had asthma?’’.
All the subjects who reported asthma without chronic
symptoms of cough and/or phlegm were not considered as
having COPD. Subjects reporting asthma and chronic
symptoms of cough and/or phlegm were considered as
having COPD with coexisting asthma.
Subjects were classified according to smoking habits as
current smokers, past smokers, and non-smokers. They were
considered smokers (current or past) if they stated in the
questionnaire that they had smoked at least 20 packs of
cigarettes or 360 g of tobacco in a lifetime, or at least one
cigarette per day or one cigar a week for 1 year. Current
smokers were those who reported currently smoking and
were divided into two subgroups according to the pack years
smoked in a lifetime (light smokers ,15 pack years;
moderate to heavy smokers >15 pack years), while a third
subgroup comprised people who were currently smoking
other tobaccos (cigars, cigarillos or pipe tobacco). Subjects
were considered past smokers if they had been smokers (as
defined above) and had stopped smoking at least 1 month
previously. All the other subjects were considered as non-
smokers. Furthermore, non-smokers and past smokers were
both divided into two subgroups according to exposure to
environmental tobacco smoke (ETS) (exposed if they
reported having been exposed for at least 4 hours per day
on most days or nights in the previous 12 months; and non-
exposed otherwise).
Table 1 Number of subjects randomly selected for the second stage of the European
Community Respiratory Health Survey and number (%) of participants
Country Centre
Subjects selected Participants
N n %
Spain Barcelona 534 393 73.6
Galdakao 576 486 84.4
Albacete 658 435 66.1
Oviedo 522 357 68.4
Huelva 478 271 56.7
France Bordeaux 2936 544 18.5
Grenoble 1165 485 41.6
Montpellier 3736 456 12.2
Paris 3113 652 20.9
Italy Pavia 816 312 38.2
Turin 518 244 47.1
Verona 504 354 70.2
Switzerland Basel 1210 853 70.5
Germany Hamburg 3312 1252 37.8
Erfurt 1076 731 67.9
Belgium Antwerp South 800 558 69.7
Antwerp City 867 564 65.1
The Netherlands Groningen 599 427 71.3
Bergen-op-Zoom 638 496 77.7
Geleen 671 439 65.4
Denmark Aarhus 652 394 60.4
Sweden Goteborg 772 682 88.3
Umea 611 552 90.3
Uppsala 709 625 88.2
Norway Bergen 969 969 100.0
Iceland Reykjavik 672 570 84.8
Ireland Dublin 599 454 75.8
UK Cambridge 527 277 52.6
Ipswich 682 448 65.7
Norwich 655 473 72.2
USA Portland 1604 734 45.8
Australia Melbourne 1644 669 40.7
New Zealand Wellington 741 481 64.9
Christchurch 712 459 64.5
Hawkes Bay 549 316 57.6
Total 36827 18412 50.0
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The other risk factors considered in the analysis were self-
reported serious respiratory infections before the age of
5 years, a history of occupational exposure to vapours, gas,
dust or fumes, and low socioeconomic class (as indicated by
having completed full time education before the age of 16
years).
The use of healthcare resources was evaluated for each
subject at the clinical interview by the following questions:
N ‘‘Have you used any medicines (inhaled medicines, pills,
capsules or tablets) to help your breathing at any time in
the last 12 months?’’
N ‘‘Have you ever been seen by a doctor because of breathing
problems or because of shortness of breath?’’
N ‘‘Have you ever visited a hospital casualty department or
emergency room because of breathing problems?’’
N ‘‘Have you ever spent a night in hospital because of
breathing problems?’’
Statistical analysis
A total of 14 855 subjects who answered the questions on
chronic symptoms during the clinical interview and who had
at least two technically satisfactory measurements of FEV1
and FVC were analysed.
Data were summarised as prevalence rates (%) with
binomial exact 95% confidence intervals. Stage II (moderate
COPD) and stage III (severe COPD) were combined as only
eight subjects were classified in stage III. The ecological
association between the prevalence rates of the GOLD stages
was evaluated at the national level by the Spearman rank
correlation coefficient (rS). Meta-analysis was performed
using the Mantel-Haenszel method to obtain pooled odds
ratios across countries for the association between sex and
GOLD stages. Pooled estimates were used when the x2 test for
heterogeneity did not reveal different patterns in the various
countries.
Multinomial regression models12 were used to assess the
association between the GOLD stages (stage 0 and stages I+)
and active/passive smoking exposure, respiratory infections
in childhood, occupational exposure, socioeconomic status,
and sex. The relative risk ratios (RRR) were also adjusted for
the effect of the ECRHS country.
The statistical analysis was performed using STATA soft-
ware, release 7.0 (StataCorp, College Station, TX, USA).
RESULTS
The overall prevalence of subjects with COPD (stages I+) was
3.6% (95% CI 3.3 to 3.9); 2.5% (95% CI 2.2 to 2.7) were in
stage I and 1.1% (95% CI 1.0 to 1.3) were in stages II–III,
while there were no cases in stage IV. The prevalence
of subjects in stage 0 was 11.8% (95% CI 11.3 to 12.3,
table 2).
The prevalence of all the stages showed a substantial and
statistically significant variation across countries: stage 0
ranged from 7.2% (95% CI 5.2 to 9.7) in Australia to 23.7%
(95% CI 21.6 to 26.0) in Spain, stage I from 0.8% (95% CI 0.2
to 1.9) in Iceland to 7.4% (95% CI 5.6 to 9.5) in Switzerland,
and stages II–III from 0.4% (95% CI 0.1 to 1.1) in Italy to
3.4% (95% CI 1.6 to 6.1) in Denmark.
In general, the geographical pattern of the prevalence of
GOLD stages was not consistent across countries. The
prevalence of chronic symptoms without obstruction (stage
0) was not significantly associated with the prevalence of
COPD stage I (rS = 0.19, p = 0.49; fig 1A), whereas stages I
and II–III were only moderately associated (rS = 0.54,
p = 0.03; fig 1B).
Women had a lower prevalence of both COPD and chronic
symptoms without obstruction than men: 2.4% (95% CI 2.1
to 2.8) v 4.8% (95% CI 4.3 to 5.3) and 10.9% (95% CI 10.2 to
11.7) v 12.6% (95% CI 11.9 to 13.4), respectively. This pattern
was consistent within all the countries except Sweden
where one centre (Uppsala) had a significantly higher
prevalence of women than men in stage 0. The pooled
estimate of the odds ratio for women v men was 0.85 (95% CI
0.77 to 0.94) for stage 0 and 0.49 (95% CI 0.41 to 0.59) for
stages I+.
Among the subjects with airflow obstruction, 32.4% (95%
CI 28.4 to 36.6) were symptomatic, 22.3% (95% CI 18.1 to
26.9) being in stage I and 54.5% (95% CI 46.6 to 62.2) in
stages II–III. The percentage of subjects with coexisting
asthma was not significantly different in stage 0 and in
stages I+: 14.1% (95% CI 12.5 to 15.8) v 12.5% (95% CI 9.8 to
15.6), respectively.
The group of patients with COPD was significantly older
and contained a higher percentage of men than did those
with stage 0 disease or normal subjects (p,0.001, table 3).
Compared with healthy individuals, subjects in stage 0 and in
stages I+ had a significantly greater prevalence of moderate
to heavy smokers, were more exposed to vapours, gas, dust or
fumes at work, reported more respiratory infections in
childhood, and were in a lower socioeconomic class. The
Table 2 Prevalence (%) with 95% confidence interval of the GOLD severity stages* for the
countries participating in the European Community Respiratory Health Survey
Stage 0 (n = 1751) Stage I (n = 369) Stages II–III (n = 168)
Spain 23.7 (21.6 to 26.0) 1.6 (1.0 to 2.4) 1.1 (0.6 to 1.7)
France 9.2 (7.9 to 10.5) 1.0 (0.6 to 1.6) 0.5 (0.3 to 1.0)
Italy 10.4 (8.3 to 12.8) 0.9 (0.4 to 1.9) 0.4 (0.1 to 1.1)
Switzerland 10.4 (8.3 to 12.8) 7.4 (5.6 to 9.5) 2.3 (1.3 to 3.6)
Germany 11.1 (9.6 to 12.7) 2.4 (1.7 to 3.2) 1.3 (0.8 to 2.0)
Belgium 11.7 (9.5 to 14.4) 3.4 (2.2 to 5.1) 2.4 (1.4 to 3.9)
The Netherlands 8.0 (6.6 to 9.6) 2.6 (1.8 to 3.6) 0.9 (0.4 to 1.5)
Denmark 12.5 (8.9 to 16.8) 4.4 (2.4 to 7.4) 3.4 (1.6 to 6.1)
Sweden 11.8 (10.2 to 13.5) 2.3 (1.6 to 3.2) 0.6 (0.3 to 1.1)
Norway 8.4 (6.7 to 10.4) 1.1 (0.5 to 2.1) 1.6 (0.9 to 2.7)
Iceland 11.0 (8.4 to 14.0) 0.8 (0.2 to 1.9) 1.1 (0.4 to 2.5)
Ireland 18.9 (14.6 to 23.8) 4.0 (2.1 to 7.0) 1.3 (0.4 to 3.4)
UK 9.8 (8.0 to 11.8) 2.3 (1.4 to 3.4) 1.0 (0.5 to 1.9)
USA 16.2 (12.6 to 20.3) 4.0 (2.2 to 6.5) 0.8 (0.2 to 2.3)
Australia 7.2 (5.2 to 9.7) 4.3 (2.8 to 6.4) 1.4 (0.6 to 2.8)
New Zealand 10.6 (8.6 to 12.9) 3.7 (2.5 to 5.2) 1.0 (0.5 to 2.0)
Total 11.8 (11.3 to 12.3) 2.5 (2.2 to 2.7) 1.1 (1.0 to 1.3)
*Eight subjects were in stage III and there were no patients in stage IV.
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crude RRRs were positively associated with stage 0 and stages
I+ for all the risk factors considered.
Following multivariate analysis, almost all the risk factors
considered were significantly associated with both stage 0
and stages I+ (table 4). The strength of the association
showed some variation between stages: subjects in stage 0
had a higher risk of being light (,15 pack years) or moderate
to heavy smokers (>15 pack years), while subjects in stages
I+ had a higher likelihood of being past or moderate to heavy
smokers and of smoking other tobaccos than did the healthy
subjects. ETS (evaluated in non-smokers and past smokers)
was moderately and homogeneously associated with both
stage 0 and COPD. Respiratory infections in childhood and
low socioeconomic class were significantly and homoge-
neously associated with both stage 0 and stages I+, whereas
occupational exposure was significantly associated only with
stage 0. After adjusting for all the risk factors, women had
the same likelihood of having only chronic symptoms as men,
while their likelihood of having airflow obstruction was
significantly lower. When the same analysis was repeated
excluding all the subjects with coexisting asthma classified in
the GOLD stages, the pattern of associations was consistent
with the main analysis (data not shown).
Compared with the group of healthy subjects, all the GOLD
stages, including stage 0, were characterised by a significantly
higher percentage of people who had visited a doctor (32.6% v
18.4%, p,0.001), had taken medication (24.1% v 14.0%,
p,0.001), had attended an emergency department (ED) at
least once and/or had had at least one hospital admission
(10.8% v 5.1%, p,0.001) because of respiratory problems.
Subjects in stage 0 and in stages I+ had a very similar use of
healthcare resources. When all the subjects with coexisting
asthma classified in the GOLD stages were excluded from the
analysis, the percentage of healthcare resource users
decreased by about one third in all the groups, whereas the
relative pattern of consumption did not change (data not
shown).
DISCUSSION
The results of our analysis show that in young adults (1) a
considerable percentage of subjects already suffered from
COPD and an even higher percentage of them reported
chronic symptoms (stage 0); (2) the severity of the disease
was still mild to moderate, with a wide variation among and
within countries; (3) stage 0 and stages I+ of the GOLD
classification of COPD identify groups of subjects that shared
a common pattern of the individual risk factors and had a
high use of healthcare resources because of respiratory
problems.
To our knowledge, this is the first international study of
almost 18 000 subjects that gives an estimate of the
prevalence of COPD according to the GOLD definition and
that focuses on the young adult population (aged 20–44
years). Based on this definition, our results support evidence
that the disease develops earlier than is usually believed. This
should be taken into account when planning future wide-
spread programmes for early detection of the disease and
preventive measures.13
The mean percentage of subjects with GOLD stage 0 was
11.8%, ranging from 7.2% in Australia to 23.7% in Spain. As
expected with this young age group, the percentage of
subjects with stages I+ disease was much lower than that of
subjects with stage 0 disease, and no subject was found in the
most severe stage (stage IV). However, despite their young
age, the percentage of subjects with stages I+ disease was
relevant (3.6%), with some countries showing a prevalence of
more than 5% (Switzerland, Belgium, Denmark, Ireland and
Australia).
Women had a lower prevalence of both chronic symptoms
(stage 0) and COPD than men, which agrees with the
findings of previous studies.14–17 The sex difference in the
prevalence was consistent across and within countries
(except Sweden), and the men/women ratio increased
significantly in the most severe stages. While the sex
difference in chronic symptoms was entirely explained by
the different distribution in exposure to the considered risk
factors (as shown in the multivariate analysis), the sig-
nificantly higher risk of having COPD for men may be due
either to the fact that they were more exposed to other
hazards (occupational, lifestyle, etc) not considered in the
present analysis or to their greater susceptibility than women.
COPD can coexist with asthma even if the inflammation
characteristic of the disease is distinct from that of asthma.18
In our sample we found that 13.7% of the subjects classified
in stages 0+ reported coexisting asthma. In these patients an
overlap between asthma and COPD may have been present,
but we could not exclude the possibility that chronic cough
and phlegm were purely expressions of asthma.
Unfortunately, because of the lack of information on diurnal
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Figure 1 Scatterplots of the prevalences (%) of COPD stage I and (A)
chronic symptoms without airflow obstruction (stage 0) and (B) COPD
stages II–III. Each symbol represents the pair of values for a single
country. Au, Australia; Be, Belgium; De, Denmark; Fr, France; Ge,
Germany; Ic, Iceland; Ir, Ireland; It, Italy; NL, The Netherlands; NZ, New
Zealand; No, Norway; Sp, Spain; Swe, Sweden; Swi, Switzerland; UK,
United Kingdom; US, United States.
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variation in symptoms or on airway hyperresponsiveness or
on inflammation, a more precise diagnosis was not achievable.
In our study the lack of relationship between stages 0 and I
and the weak relationship between stage I and stages II–III
suggest that the progression from less to more severe stages is
not a straight process affecting all patients. Likewise, many
patients in stages I+ did not report chronic symptoms, either
because they did not have them or because they did not
recognise them.4 19 20 These findings apparently agree with
the results of the retrospective cohort study by Vestbo et al,21
which made the authors conclude that GOLD stage 0 is of
little help in identifying subjects at risk for COPD, while
cigarette smoking itself remains the best predictor. However,
the cross sectional nature of our data compels caution in
interpreting the findings and cannot contribute to evaluation
of the prognostic value of stage 0. In our opinion, this crucial
point regarding aspects of global health policy requires truly
prospective studies such as the ongoing ECRHS II. Our data
can only spotlight the impressively high prevalence of
subjects in stage 0, which represents an important health
problem, as confirmed by the high use of healthcare
resources found in these subjects.22
On the other hand, subjects in stage 0 shared the same risk
factors as patients with COPD. Active smoking was strongly
associated with both stage 0 and stages I+ COPD. The overall
pattern of the association between smoking exposure and the
GOLD stages strongly suggests that patients with more severe
disease had given up smoking or had changed type of
tobacco. Respiratory infections in childhood and low social
class showed the same degree of association with both stage
0 and stages I+, as did ETS exposure which was moderately
and positively associated with both stage 0 and stages I+ in
non- and past smokers. At variance, after adjusting for the
other risk factors, occupational exposure was associated with
stage 0 but not with COPD, probably because more
susceptible subjects were not employed in the most danger-
ous jobs (healthy worker effect) or because the question we
used was not properly stated.
Table 3 Main characteristics of the subjects considered in the analysis according to the GOLD severity stages, and crude
relative risk ratios (RRR)* with 95% confidence intervals for the association between each risk factor and the GOLD severity
stage
No respiratory
disorders
(n = 12567) %
Stage 0 (n = 1751) Stages I+ (n = 537)
% RRR (95% CI) % RRR (95% CI)
Active/passive smoking exposure:
Non-smokers and ETS2 37.9 21.4 1.00 24.0 1.00
Past smokers and ETS2 17.3 10.2 1.05 (0.87 to 1.27) 15.6 1.42 (1.07 to 1.89)
Non-smokers and ETS+ 7.5 5.4 1.29 (1.02 to 1.64) 5.0 1.06 (0.69 to 1.62)
Past smokers and ETS+ 4.4 3.1 1.23 (0.91 to 1.67) 4.0 1.45 (0.91 to 2.33)
Smokers (,15 pack years) 19.9 28.5 2.55 (2.20 to 2.94) 14.4 1.15 (0.86 to 1.53)
Smokers (>15 pack years) 11.5 30.1 4.65 (4.01 to 5.38) 33.5 4.58 (3.62 to 5.81)
Smokers (other tobaccos)` 1.5 1.3 1.47 (0.93 to 2.31) 3.5 3.50 (2.09 to 5.86)
Presence of respiratory infections
before the age of 5 years
8.9 12.2 1.47 (1.26 to 1.72) 14.1 1.71 (1.32 to 2.20)
Presence of occupational exposure
to vapours, gas, dust or fumes in a lifetime
41.6 54.4 1.67 (1.51 to 1.85) 52.3 1.54 (1.29 to 1.83)
Low socioeconomic class 19.5 29.0 1.68 (1.50 to 1.89) 28.0 1.60 (1.30 to 1.97)
Females 51.1 46.3 33.7
Mean (SD) age (years) 33.6 (7.2) 33.2 (7.1) 36.8 (6.5)
Mean (SD) FEV1 % predicted 106.6 (13.1) 103.9 (13.1) 86.6 (15.1)
*Calculated by multinomial regression models (reference population: subjects with neither chronic symptoms nor airflow obstruction).
ETS+/2: subjects exposed/not exposed to environmental tobacco smoke.
`Cigars, cigarillos or pipe tobacco.
Table 4 Mutually adjusted relative risk ratios (RRRs)* (with 95% confidence intervals) for the association between the GOLD
severity stages and active/passive smoking exposure, respiratory infections before the age of 5 years, occupational exposure to
vapours, gas, dust or fumes in a lifetime, socioeconomic class, and sex
RRR (95% CI)
Comparison between
RRRsStage 0 Stages I+
Active/passive smoking exposure (v non-smoker and ETS2)`
Past smoker and ETS2 1.05 (0.86 to 1.27) 1.39 (1.04 to 1.86) 0.101
Non-smoker and ETS+ 1.18 (0.92 to 1.51) 1.16 (0.75 to 1.80)
0.77
Past smoker and ETS+ 1.15 (0.84 to 1.56) 1.41 (0.86 to 2.29)
Smoker (,15 pack years) 2.38 (2.05 to 2.77) 1.22 (0.90 to 1.65)
Smoker (>15 pack years) 4.15 (3.55 to 4.84) 4.09 (3.17 to 5.26) ,0.001
Smoker (other tobaccos)** 1.45 (0.91 to 2.31) 3.25 (1.91 to 5.53)
Respiratory infections (present v absent) 1.47 (1.25 to 1.74) 1.62 (1.24 to 2.12) 0.53
Occupational exposure (present v absent) 1.47 (1.31 to 1.65) 1.08 (0.88 to 1.31) 0.006
Socioeconomic class (low v high) 1.22 (1.07 to 1.40) 1.34 (1.05 to 1.71) 0.51
Sex (female v male) 1.00 (0.89 to 1.12) 0.55 (0.45 to 0.67) ,0.001
*Also adjusted for the effect of the ECRHS countries (reference population: subjects with neither chronic symptoms nor airflow obstruction).
p values obtained by the Wald test.
`ETS+/2: presence/absence of exposure to environmental tobacco smoke.
1p value for comparison between the adjusted RRRs for past smoking.
p value for comparison between the adjusted RRRs for exposure to environmental tobacco smoke.
**Cigars, cigarillos. or pipe tobacco.
p value for comparison between the adjusted RRRs for current smoking.
}
}
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Subjects with stage 0 and stages I+ disease used more
healthcare resources because of respiratory problems than
did healthy people. Those with stage 0 disease had the same
utilisation of healthcare resources as individuals with stages
I+ disease, even when the subjects with coexisting asthma
were not considered, suggesting that the presence of chronic
symptoms of cough and/or phlegm was the main reason for
using healthcare services by patients of this age group with
mild to moderately severe COPD.
One potential problem in interpreting our results is that
there was a large variation in response rates across countries.
A low response rate may lead to considerable overestimation
or underestimation of the actual prevalence if participation in
the survey is related to the presence of symptoms.23 However,
previous studies have shown that the effect of non-response
was negligible in the second stage of ECRHS.24 25 A further
limitation that should be taken into account when consider-
ing the prevalence estimates at national level is that the centres
were not selected to be representative of their countries
and that, in some countries, only one centre was present.
In conclusion, COPD is an important health problem even
in young adults, both because of the high prevalence of the
disease and the frequent use of healthcare resources. Our
study shows that GOLD stage 0 identifies a particular group
of subjects exposed to the same risk factors as those with
COPD and characterised by requiring medical assistance for
respiratory problems as frequently as do COPD patients.
The ongoing follow up of these subjects in ECRHS II8 will
highlight the natural history of individuals in the different
GOLD stages and will offer the possibility of assessing the like-
lihood of those in stage 0 progressing to more severe stages.
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